Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Computational Exploration of Potential CFTR Binding Sites for Type I Corrector Drugs.

Biochemistry - 15 Aug 2023

Lester Anna, Sandman Madeline, Herring Caitlin, Girard Christian, Dixon Brandon, Ramsdell Havanna, Reber Callista, Poulos Jack, Mitchell Alexis, Spinney Allison, Henager Marissa E, Evans Claudia N, Turlington Mark, Johnson Quentin R

Abstract excerpt

Cystic fibrosis (CF) is a recessive genetic disease that is caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The recent development of a class of drugs called "correctors", which repair the structure and function of mutant CFTR, has greatly enhanced the life expectancy of CF patients. These correctors target the most common disease causing CFTR mutant F508del and are...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aminopyridines
Share to Benzodioxoles

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Binding Sites

Share to Cryoelectron Microscopy

Share to Cystic Fibrosis

Share to Cystic Fibrosis Transmembrane Conductance Regulator

Share to Ligands

Share to Mutation

Source

Open in PubMed Open full text

Identifiers

PMID: 37437308
DOI: 10.1021/acs.biochem.3c00165
PMCID: PMC10433520

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Computational Exploration of Potential CFTR Binding Sites for Type I Corrector Drugs.PMID 37437308Read ↗

Mechanism-based corrector combination restores ΔF508-CFTR folding and function.Semantic proximity Read ↗

Elucidation of Global Trends in the Effects of VX-661 and VX-445 on the Expression of Clinical CFTR VariantsSemantic proximity Read ↗

Comprehensive mapping of cystic fibrosis mutations to CFTR protein identifies mutation clusters and molecular docking predicts corrector binding site.Semantic proximity Read ↗

Comprehensive mapping of Cystic Fibrosis mutations to CFTR protein identifies mutation clusters and molecular docking predicts corrector binding siteSemantic proximity Read ↗

Structure-based discovery of CFTR potentiators and inhibitorsSemantic proximity Read ↗

In Silico Evaluation of Lumacaftor for Cystic FibrosisSemantic proximity Read ↗

A Novel, Uniquely Efficacious Type of CFTR Corrector with Complementary Mode of ActionSemantic proximity Read ↗

Mechanism of CFTR correction by type I folding correctorsSemantic proximity Read ↗

A uniquely efficacious type of CFTR corrector with complementary mode of action.Semantic proximity Read ↗

Structure-guided combination of novel CFTR correctors to improve the function of F508del-CFTR in airway epithelial cells.Semantic proximity Read ↗

Structural identification of a hotspot on CFTR for potentiationSemantic proximity Read ↗

Mechanism of CFTR correction by type I folding correctors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.